Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Oncology
Filter     Order     Display # 
Date Item Title
15 Sep 2008 Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
15 Sep 2008 Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
15 Sep 2008 Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
15 Sep 2008 F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
15 Sep 2008 Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
15 Sep 2008 Elesclomol Two-Year Survival and Integrated Safety Data Presented at the 33rd Congress of the European Society for Medical Oncology
15 Sep 2008 Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008
15 Sep 2008 Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology
11 Sep 2008 CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
11 Sep 2008 Merck KGaA Submits New License Application for Erbitux in Firstline Non-Small Cell Lung Cancer in Europe
11 Sep 2008 Calando Pharmaceuticals Phase II Clinical Study Opens to Patient Enrollment
11 Sep 2008 Novacea Update on Asentar(TM)
10 Sep 2008 Argos Therapeutics Initiates Phase 2 Trial in Renal Cell Carcinoma for its Arcelis(TM) Personalized Immunotherapy Platform
10 Sep 2008 Ortho Biotech Files sNDA for DOXIL(R) for the Treatment of Advanced Breast Cancer
09 Sep 2008 RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
09 Sep 2008 Hana Biosciences' rALLy Clinical Trial of Marqibo Meets Response Criteria to Advance to Full Enrollment
08 Sep 2008 VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma
08 Sep 2008 Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
08 Sep 2008 FivePrime Initiates Phase I Clinical Trial of FP-1039 in Patients With Advanced Cancers
08 Sep 2008 Bostwick Therapeutics Announces Initiation of Novel Phase I/II Personalized Medicine Immunotherapy Trial for Advanced Prostate Cancer
08 Sep 2008 Ortho Biotech Files sNDA for DOXIL(R) for the Treatment of Advanced Breast Cancer
07 Sep 2008 Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
07 Sep 2008 OncoMune Publishes Positive Results of OCM-8054
04 Sep 2008 QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) In Women With Postmenopausal Vaginal Syndrome
04 Sep 2008 Antisoma starts phase II trial of AS1411 in renal cancer
03 Sep 2008 Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
03 Sep 2008 ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
02 Sep 2008 Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
02 Sep 2008 OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
02 Sep 2008 Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
31 Aug 2008 CYCLACEL announces recommendations of data review committee for seliciclib Phase 2b non-small cell lung cancer APPRAISE trial
31 Aug 2008 ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
28 Aug 2008 Algeta Reports Positive Headline Phase II Data on Pain Palliation with Alpharadin
27 Aug 2008 Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer
27 Aug 2008 Start of Prolarix(TM) phase 2 study in liver cancer
27 Aug 2008 Glivec receives FDA priority review as first therapy to reduce recurrence of gastrointestinal stromal tumors after surgery
27 Aug 2008 SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
26 Aug 2008 Novosom AG acquires exclusive license from Isis Pharmaceuticals, Inc. for CD40-targeted antisense inhibitors
26 Aug 2008 Curis Announces Dosing of First Patient in Phase I Clinical Trial of CUDC-101
26 Aug 2008 Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
25 Aug 2008 FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
25 Aug 2008 AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers
25 Aug 2008 The Multiple Myeloma Research Consortium (MMRC) Partners With Celgene Corporation on Phase I/II Trial of Pomalidomide (CC-4047) in Relapsed and Refractory Multiple Myeloma Patients
24 Aug 2008 Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
24 Aug 2008 ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
24 Aug 2008 Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone
24 Aug 2008 Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
21 Aug 2008 New Trial to Evaluate Nexavar(R) as Adjuvant Therapy in Liver Cancer
21 Aug 2008 NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
21 Aug 2008 VIDAZA(R) Receives Expanded FDA Approval to Include Overall Survival in Higher-Risk MDS
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 151 - 200 of 2757

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics